Trials / Completed
CompletedNCT04019041
A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 153 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study further evaluates the efficacy of bermekimab in treating moderate to severe hidradenitis suppurativa in adults. 1/3 of patients will receive weekly injections of bermekimab, 1/3 will receive alternating every other week injections of bermekimab or placebo, and 1/3 will receive weekly injections of placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bermekimab | bermekimab 2 mL (200 mg/mL) pre-filled syringe |
| DRUG | placebo | placebo 2 mL pre-filled syringe |
Timeline
- Start date
- 2019-09-16
- Primary completion
- 2020-05-19
- Completion
- 2020-11-17
- First posted
- 2019-07-15
- Last updated
- 2023-07-27
- Results posted
- 2023-07-27
Locations
33 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04019041. Inclusion in this directory is not an endorsement.